{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:35:03Z","timestamp":1790699703270,"version":"4.1.0"},"reference-count":37,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["ASSAY and Drug Development Technologies"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:p>\n                    <jats:italic toggle=\"yes\">\n                      Neurodegenerative disorders such as Alzheimer\u2019s and Parkinson\u2019s disease remain a significant therapeutic challenge due to the restrictive nature of the blood\u2013brain barrier (BBB) and the limited efficacy of current pharmacological treatments. Intranasal administration has emerged as a promising noninvasive strategy that enables direct drug delivery to the brain by bypassing the BBB. This study aimed to design and optimize a dual-drug nasal hydrogel containing metformin hydrochloride, a hydrophilic AMP-activated protein kinase activator, and curcumin, a lipophilic antioxidant and anti-amyloid agent, and to provide synergistic neuroprotection. The formulation was prepared using carbopol as the gel matrix and characterized in terms of physicochemical stability, drug content uniformity, rheology,\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      release, and excipient compatibility. A Box\u2013Behnken design was used to systematically evaluate the effects of carbopol, glycerin, and curcumin concentrations on critical quality attributes. The optimized hydrogel exhibited acceptable pH, viscosity suitable for nasal administration, and sustained biphasic drug release with a cumulative 6-h release of approximately 85% for metformin and 39% for curcumin according to the Higuchi drug release model (\n                      <jats:italic toggle=\"yes\">R<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      &gt; 0.98). Collectively, these results highlight the feasibility of an integrative intranasal hydrogel platform to overcome the bioavailability challenges of both agents. The proposed system offers a patient-friendly, noninvasive approach for potential nose-to-brain therapy in neurodegenerative disorders and warrants further preclinical and\n                      <jats:italic toggle=\"yes\">in\u00a0vivo<\/jats:italic>\n                      investigation.\n                    <\/jats:italic>\n                  <\/jats:p>","DOI":"10.1177\/1540658x261429259","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:53:53Z","timestamp":1773251633000},"page":"323-333","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["A Nasal Hydrogel Combining Metformin and Curcumin for Potential Nose-to-Brain Therapy in Neurodegenerative Disorders"],"prefix":"10.1177","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1791-3055","authenticated-orcid":false,"given":"Emine Dilek","family":"\u00d6zy\u0131lmaz","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Department of Pharmaceutical Technology, Eastern Mediterranean University, North Cyprus, Famagusta, Mersin 10, T\u00fcrkiye."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031851"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bspc.2022.104223"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40005-022-00589-5"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112905"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.138887"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202303043"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e17873"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106348"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae367"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11020135"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116034"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13647-7"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph18040486"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00641-6"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1039\/D0MH01029D"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cemconres.2025.107926"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/03639045.2015.1132227"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.33483\/jfpau.1195397"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13081215"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26083641"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/gels8030168"},{"key":"e_1_3_2_23_1","volume-title":"ICH harmonised tripartite guideline: Stability testing of new drug substances and products Q1A(R2).","author":"International Conference on Harmonisation (ICH)","year":"2003","unstructured":"22.International Conference on Harmonisation (ICH). 2003. ICH harmonised tripartite guideline: Stability testing of new drug substances and products Q1A(R2). Geneva: ICH Secretariat."},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodhyd.2024.109814"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/gels8040223"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2022.09.101"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/polym15092203"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081742"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46032"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.2c07062"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/plants11141809"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106623"},{"key":"e_1_3_2_33_1","volume-title":"Guideline on the pharmaceutical quality of inhalation and nasal medicinal products","author":"European Medicines Agency","year":"2022","unstructured":"32.European Medicines Agency. 2022. Guideline on the pharmaceutical quality of inhalation and nasal medicinal products. European Medicines Agency."},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/fluids4010003"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2013.09.030"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/polym16243451"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.123345"}],"container-title":["ASSAY and Drug Development Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1540658X261429259","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1540658X261429259","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1540658X261429259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T09:06:18Z","timestamp":1779008778000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1540658X261429259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5,1]]}},"alternative-id":["10.1177\/1540658X261429259"],"URL":"https:\/\/doi.org\/10.1177\/1540658x261429259","relation":{},"ISSN":["1540-658X","1557-8127"],"issn-type":[{"value":"1540-658X","type":"print"},{"value":"1557-8127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]}}}